CMS Open Payments · Program Year 2024
Dutch Ophthalmic Research Center (International) B.V.
Dutch Ophthalmic Research Center (International) B.V. reported $12,128.07 across General Payments, Research, and Ownership to 29 physicians and teaching hospitals across 29 transactions.
- $12.1K
- All-tracks total
- 29
- Transactions
- 29
- Recipients
- +$7.1K
- General Payments vs PY2023
Dutch Ophthalmic Research Center (International) B.V. reported $12,128.07 across all CMS Open Payments tracks (General + Research + Ownership) to 29 physicians and teaching hospitals in Program Year 2024 - ranking #1614 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $12,128.07, averaging $418.21 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer dutch-ophthalmic-research-center-international-b-v Dutch Ophthalmic Research Center (International) B.V.
$12.1K · #1614/1,925 · 0.0% industry · PY2024
- TOT $12.1K
- RANK #1614
- SHARE 0.0%
- TXN 29
- RCP 29
- CAT 3
- GEN $12.1K
- ΔGEN +$7.1K
- TOP1 78.6%
- PY 2024
Volume peers
Nearest volume peer: Smaio USA Corporation ($12.2K)
Dutch Ophthalmic Research Center (International) B.V. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Dutch Ophthalmic Research Center (International) B.V.'s CMS-reported General Payments increased by $7.1K (+140.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DUTCH OPHTHALMIC RESEARCH CENTER (INTERNATIONAL) B.V.PY2023: DUTCH OPHTHALMIC RESEARCH CENTER (INTERNATIONAL) B.V.PY2024: Dutch Ophthalmic Research Center (International) B.V.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $5,046.21
- PY2024
- $12,128.07
What the Data Shows for Dutch Ophthalmic Research Center (International) B.V.
Averaging $418.21 per transaction and $418.21 per recipient, Dutch Ophthalmic Research Center (International) B.V.'s Program Year 2024 total comes to $12,128.07 across 29 transactions and 29 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1614 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $8.3K, accounting for 68.2% of this company's General Payments and 16 transactions.
General Payment Breakdown by Type
Across 3 types of general payments, Dutch Ophthalmic Research Center (International) B.V.'s largest category was "Travel and Lodging" at $8.3K - 68.2% of General Payments.
How Dutch Ophthalmic Research Center (International) B.V. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $8.3K | 16 | 68.2% |
| Consulting Fee | $3.4K | 1 | 27.8% |
| Food and Beverage | $484.25 | 12 | 4.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $12,128.07 (100.0%) of $12,128.07 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Dutch Ophthalmic Research Center (International) B.V.
The five named recipients with the highest reported General Payments from this company
- 1
Christopher D Riemann
$9,535.79 across 7 reported transactions
- 2
Farrell Clifton Tyson
$1,339.85 across 5 reported transactions
- 3
Dilraj S Grewal
$1,231.22 across 16 reported transactions
- 4
Courtney M Crawford
$21.21 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Dutch Ophthalmic Research Center (International) B.V.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dutch Ophthalmic Research Center (International) B.V..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Dutch Ophthalmic Research Center (International) B.V..
Showing 6 of 1,924 companies with CMS-reported payment data.
Astellas Pharma Europe BV
Validus Pharmaceuticals LLC
Blue Surgical Llc
Pfizer S.a.
Sentec, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.